This activity is intended for allergists, immunologists, and other clinicians involved in the diagnosis and treatment of patients with severe asthma.

Distinguish IPF from mimickers using guideline-recommended, multidisciplinary diagnostic evaluation approaches

Outline emerging data for currently approved as well as investigational therapy and discuss their clinical implications in the management of patients with RA Utilize evidence-based care to improve and personalize management of patients with RA, including management of comorbid conditions

Evaluate recommendations for early assessment and diagnosis for patients with EGPA.

A survey issued by the American Academy of Allergy Asthma and Immunology and Immune Deficiency Foundation found that only 4% of primary care practitioners were aware that guidelines existed for the diagnosis and management of primary immunodeficiency.

This activity series presents the common challenges of diagnosing and managing progressive fibrotic interstitial lung disease subtypes of IPF and SSc-ILD . There is at present no cure for IPF or SSc-ILD and existing treatments focus on delaying disease progression, controlling symptoms and preventing complications.

Gain insights into the importance of early diagnosis and early highly efficacious treatment of PF-ILD to improve lung function and quality of life

Wondering if you should alter medications for your patients with severe asthma? The activity now includes an important update on how to manage patients with severe asthma during COVID-19! Learn the latest recommendations about NSAIDs, steroids and nebulizers for patients with asthma and COVID-19.